» Articles » PMID: 8500741

Ablation of Persistent Hepatitis B by Bone Marrow Transplantation from a Hepatitis B-immune Donor

Overview
Specialty Gastroenterology
Date 1993 Jun 1
PMID 8500741
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hepatitis B virus (HBV) infection is still a major cause of liver disease for which no definite therapy is available. We describe here a hepatitis B surface antigen (HBsAg) carrier patient with active viral replication (HBV DNA positive) who was treated for leukemia by bone marrow transplantation (BMT) from an HBV immune donor. Following BMT from the antibody to hepatitis B core antigen (anti-HBc) positive/anti-HBs positive bone marrow donor, immune reconstitution of the recipient's bone marrow resulted in clearance of the circulating HBsAg, as well as HBV DNA. The patient acquired immunity against HBV, which lasted for more than 8 months posttransplantation. Therefore, this report provides evidence that adoptive transfer of specific immunity against HBV through allogeneic BMT may lead to clearance of persistent HBV infection. Furthermore, the data support the hypothesis that the HBsAg carrier state is most probably the result of an inefficient immune response against HBV, implying that clearance of HBV may be facilitated by adoptive cellular immunotherapy.

Citing Articles

Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.

Mooney A, Draper S, Burn O, Anderson R, Compton B, Tang C JHEP Rep. 2024; 6(5):101038.

PMID: 38694959 PMC: 11061331. DOI: 10.1016/j.jhepr.2024.101038.


Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality.

Bakacs T, Safadi R, Puskas L, Feher L, Kovesdi I Cureus. 2022; 14(3):e22750.

PMID: 35371882 PMC: 8970536. DOI: 10.7759/cureus.22750.


CD4 T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy.

Buschow S, Jansen D Cells. 2021; 10(5).

PMID: 34066322 PMC: 8148211. DOI: 10.3390/cells10051114.


A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation.

Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N Bone Marrow Transplant. 2020; 55(7):1388-1398.

PMID: 32071416 PMC: 7329632. DOI: 10.1038/s41409-020-0833-5.


Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Moreno-Cubero E, Larrubia J World J Gastroenterol. 2016; 22(28):6469-83.

PMID: 27605882 PMC: 4968127. DOI: 10.3748/wjg.v22.i28.6469.